Arovella Therapeutics (ALA) Q3 2025 earnings summary

Executive summary

• Lead program ALA-101, an iNKT cell therapy, is advancing toward phase I clinical trials in 2025 for CD19-positive blood cancers, with a proprietary clinic-ready manufacturing process established and strong preclinical efficacy in lymphoma models.

• The company is expanding its platform to target solid tumors, notably with the CLDN18.2 CAR program, and integrating IL-12-TM armoring technologies, supported by a sponsored research agreement with UNC.

• Recent capital raise of AUD 15 million ($15 million) ensures funding for full phase I enrollment and initial safety/efficacy data readouts.

• Appointment of a Senior Director of Clinical Development and formation of a clinical advisory board to optimize trial design and execution.

• Successfully transferred ALA-101 manufacturing to a cGMP environment and completed key IND-enabling studies.

Financial highlights

• Ended the quarter with AUD 23.5 million ($23.5 million) in cash, providing a strong financial position and an estimated 9.8 quarters of funding at current burn rate.

• Net cash outflow from operating activities for the quarter was $2.4 million, with R&D and staff costs comprising 87% of outflows.

• Successfully completed an AUD 15 million ($15 million) placement to fund clinical development and IND-enabling studies, issuing 120 million shares at $0.125 per share with attaching options.

• Payments to related parties totaled $178,226 for the quarter, covering director and executive compensation.

Outlook and guidance

• Fully funded to complete enrollment and report initial safety and efficacy data for the phase I ALA-101 trial, expected to commence in 2025.

• IND submission for ALA-101 targeted for Q2, with phase I trial initiation expected in 2025.

• Anticipates presenting proof-of-concept data for the CLDN18.2-CAR-iNKT cell gastric cancer program and advancing IL-12-TM armoring technology.

• Plans to accelerate development of CLDN18.2 and other solid tumor programs, with animal and in vitro data expected in the coming months.

• Continues to review and acquire novel technologies to enhance or broaden the CAR-iNKT platform.